News

Haggling about location ended
Enlarge image

PoliticsEUFranceGermanyUK

Haggling about location ended

03.07.2012 - No chunks for noone, nuggets for Paris, London and Munich. The EU commission finally agreed on the setting for the proposed EU patents court.

On 29 June at the European Council in Brussels, Belgium, the EU heads of state agreed on a plan to implement a so far only proposed EU patents court which now could become functional in 2014. Currently, the European Patent Office (EPO) has responsibility for the examination and grant of 'European' patents, but once those patents are granted they become an individual patent in each country selected by the proprietor. Should the proprietors of the patents wish to enforce them they must do so in each country individually. The new court will maintain divisions in three different countries with France coming up with the most important one. The central division of the Court of First Instance (CFI) of the Unified Patent Court (UPC) will be - together with the CFI-president's office in Paris. Subdivisions handling chemistry and pharmaceutics industry as well as mechanical engineering will be installed in London and Munich, respectfully. Although Munich has already the headquarters of the EPO the heavy lobbying for Munich as the place for a EU patents court did not suceed in the end.

The long awaited EU patents court will facilitate the introduction of patents with a unitary effect across the member states. However, Italy and Spain are excluded so far because they diagree with the current language arrangements. Uninvolved of the patents court agreement the unitary patent itself has to be approved by the European Parliament and the Council of Ministers. The crucial step is the vote in the parliament on 3 and 4 July. The then following Council approval is merely a formality.

http://www.european-biotechnology-news.com/news/news/2012-03/haggling-about-location-ended.html

BusinessUK

20.08.2014 Biopharmaceutical contract manufacturer Fujifilm Diosynth Biotechnologies is expanding its cell culture manufacturing capacity further with a new 2,000l single-use bioreactor at the company’s site in Billingham, UK.

BusinessEUGermanyUK

15.08.2014 Some of Europe’s biggest pharma companies are competing in a bidding war for US biotech Intermune Inc., Bloomberg reports, citing insider reports as the source.

ResearchEUGermanyUK

13.08.2014 The Ebola epidemic is still raging on in West Africa and thus far there is

neither vaccine nor cure for the viral disease. The only flickers of hope:

an experimental antibody serum and an early-stage vaccine.

BusinessFrance

11.08.2014 Will Sanofi succeed where Pfizer failed? The French pharmaceutical company has taken on the commercialisation of Mannkind Corporation’s inhaled insulin product Afrezza.

ResearchSwedenGermany

08.08.2014 Boehringer Ingelheim is walking away from Swedish Orexo's prostaglandin inhibition project OX-MPI. Germany's largest researching pharmaceutical company had been responsible for the project's research and development since 2005.

ResearchSwitzerlandDenmark

06.08.2014 Roche is re-expanding its involvement in RNAi technologies. The Swiss pharmaceutical company will pay up to €335m for the acquisition of the Danish company Santaris Pharma A/S.

ResearchUKSwitzerland

03.08.2014 In its efforts to become the leading country in genetic research, the UK has attracted investments worth more than £300m (€376m) to map 100,000 human genomes by 2017.

BusinessSpainUKSweden

31.07.2014 Astrazeneca is buying the rights to Almirall’s respiratory drugs in a deal worth up to €1.56bn.

BusinessFranceGermanySwitzerlandUK

30.07.2014 Rumours have it that French Danone wants to sell its medical nutrition business to US drugmaker Hospira for US$5bn in yet another tax inversion deal.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • 4SC1.23 EUR6.03%
  • VITA 343.96 EUR4.49%
  • WILEX2.36 EUR4.42%

FLOP

  • CYTOS0.26 CHF-3.70%
  • MOLOGEN7.10 EUR-2.74%
  • ADDEX4.00 CHF-1.72%

TOP

  • SANTHERA82.95 CHF19.7%
  • MAGFORCE6.50 EUR10.2%
  • LONZA101.10 CHF7.1%

FLOP

  • MOLOGEN7.10 EUR-24.5%
  • WILEX2.36 EUR-24.4%
  • 4SC1.23 EUR-15.2%

TOP

  • SANTHERA82.95 CHF3850.0%
  • CO.DON2.50 EUR228.9%
  • PAION2.48 EUR198.8%

FLOP

  • CYTOS0.26 CHF-93.5%
  • MEDIGENE4.65 EUR-67.7%
  • MERCK KGAA64.40 EUR-45.7%

No liability assumed, Date: 21.08.2014